Rigel Downsizes R&D To Ready Fostamatinib Commercial Effort
Executive Summary
Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.